Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enveric Biosciences Inc (NQ: ENVB ) 0.4750 +0.0097 (+2.08%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enveric Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives November 29, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry November 27, 2023 From Enveric Biosciences Via Business Wire Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Via Benzinga Topics Cannabis Exposures Cannabis Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) November 24, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials November 14, 2023 Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its... Via Benzinga Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results November 13, 2023 From Enveric Biosciences, Inc. Via Business Wire Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More November 12, 2023 Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? Via Benzinga Topics Initial Public Offering Exposures Securities Market Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More November 06, 2023 DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court Via Benzinga Topics Economy Exposures Interest Rates Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Enveric Biosciences to Present at the Centurion One 5th Global Summit October 20, 2023 From Enveric Biosciences Via Business Wire Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders October 18, 2023 From Enveric Biosciences Via Business Wire Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit October 11, 2023 From Enveric Biosciences Via Business Wire Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More October 06, 2023 Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session October 04, 2023 Via Benzinga Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates October 03, 2023 From Enveric Biosciences Via Business Wire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry September 27, 2023 From Enveric Biosciences Via Business Wire Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates 12 Health Care Stocks Moving In Thursday's After-Market Session September 21, 2023 Via Benzinga Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here September 21, 2023 The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its... Via Benzinga Topics Derivatives Intellectual Property Exposures Derivatives Intellectual Property Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates September 20, 2023 From Enveric Biosciences Via Business Wire Porch Group And 2 Other Stocks Under $3 Insiders Are Buying September 20, 2023 The Dow Jones closed lower by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More September 18, 2023 Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next Via Benzinga Exposures Product Safety Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 September 18, 2023 From Enveric Biosciences Via Business Wire Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives September 11, 2023 From Enveric Biosciences Via Business Wire Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives September 05, 2023 From Enveric Biosciences Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
